Posted On: 05/17/2016 12:34:11 PM
Post# of 72443
Pfizer's Anacor deal showcases new wave of eczema therapies
"More than two dozen drugmakers are working on novel medicines to treat the condition affecting about 20 million Americans, also known as atopic dermatitis, and Pfizer's $5.2 billion deal positions it to become a market leader.
Anacor's steroid-free topical ointment crisaborole is the first of the new treatments to be reviewed by U.S. regulators. An injectable therapy called dupilumab from Regeneron Pharmaceuticals Inc (REGN.O) is expected to be submitted for U.S. approval later this year."
http://www.reuters.com/article/us-health-ecze...SKCN0Y80CX
Go B-acne! With potential treatment in ABSSSI, OM, UP and acne, Brilacidin will be a $10B+ drug when all is said and done.
"More than two dozen drugmakers are working on novel medicines to treat the condition affecting about 20 million Americans, also known as atopic dermatitis, and Pfizer's $5.2 billion deal positions it to become a market leader.
Anacor's steroid-free topical ointment crisaborole is the first of the new treatments to be reviewed by U.S. regulators. An injectable therapy called dupilumab from Regeneron Pharmaceuticals Inc (REGN.O) is expected to be submitted for U.S. approval later this year."
http://www.reuters.com/article/us-health-ecze...SKCN0Y80CX
Go B-acne! With potential treatment in ABSSSI, OM, UP and acne, Brilacidin will be a $10B+ drug when all is said and done.
(2)
(0)
Scroll down for more posts ▼
